Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.56 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | NOS3 | P29474 | 1/20 | 0.47 |
| ▸ | NOS1 | P29475 | 1/20 | 0.47 |
| ▸ | NOS2 | P35228 | 1/20 | 0.47 |
| ▸ | BCHE | P06276 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6204203 | 0.83 | KDM4E (0.55) | HRH3BCHEACHERAB9ANPC1 | |
| SCHEMBL5391233 | 0.80 | ALDH1A1 (0.47) | SMN1; SMN2HTTBCHEACHERAB9A | |
| SCHEMBL12646166 | 0.80 | HRH3 (0.61) | SMN1; SMN2HRH3HTTNOS3NOS1 | |
| SCHEMBL6205128 | 0.79 | ALDH1A1 (0.57) | SMN1; SMN2HTTBCHEACHETSHR | |
| SCHEMBL4547887 | 0.79 | HRH3 (0.65) | SMN1; SMN2HRH3HTTNOS3NOS1 | |
| SCHEMBL10077424 | 0.78 | HRH3 (0.59) | SMN1; SMN2HRH3HTTNOS3NOS1 | |
| SCHEMBL4923116 | 0.78 | CYP2C19 (0.58) | SMN1; SMN2HTTKMT2AMEN1LMNA | |
| SCHEMBL15467001 | 0.78 | HRH3 (0.87) | SMN1; SMN2HRH3NOS3NOS1NOS2 | |
| SCHEMBL19441582 | 0.78 | HRH3 (0.62) | SMN1; SMN2HRH3HTTNOS3NOS1 | |
| SCHEMBL19441606 | 0.78 | HRH3 (0.62) | SMN1; SMN2HRH3HTTNOS3NOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1551841-A1 | PYRAZOLOPYRIMIDINES AS KINASE INHIBITORS | SmithKline Beecham Corporation (US) | 2005-07-13 | — | — | EP | disclosed |
| WO-2004009602-A1 | PYRAZOLOPYRIMIDINES AS KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-01-29 | — | — | WO | disclosed |
| US-6645989-B2 | Antiinflammatory agents | SMITHKLINE BEECHAM CORPORATION | 2003-11-11 | — | — | US | disclosed |
| US-20030064997-A1 | Novel compounds | SMITHKLINE BEECHAM CORPORATION | 2003-04-03 | — | — | US | disclosed |
| US-6268370-B1 | CYTOKINE MEDIATED DISEASES | SMITHKLINE BEECHAM CORPORATION | 2001-07-31 | — | — | US | disclosed |
| US-5916891-A | CYTOKINE MEDIATED DISEASES | SMITHKLINE BEECHAM CORPORATION (US) | 1999-06-29 | — | — | US | disclosed |
| US-5686455-A | Imidazole derivatives and their use as cytokine inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 1997-11-11 | — | — | US | disclosed |
| US-5656644-A | CYTOKINE SUPPRESSORS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-08-12 | — | — | US | disclosed |
| EP-0623126-A1 | IMIDAZOLE DERIVATIVES AND THEIR USE AS CYTOKINE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1994-11-09 | — | — | EP | disclosed |
| WO-1993014081-A1 | IMIDAZOLE DERIVATIVES AND THEIR USE AS CYTOKINE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1993-07-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030064997-A1 | Novel compounds | BRD4, BRDT, HDAC6 | SMN1; SMN2 1443/4885HRH3 1524/4885HTT 2705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.